The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Advancing Nuclear Medicine through Innovation
FIGURE 1.1 DOE-OBER funding for nuclear medicine research, 2002—2007. SOURCE: Data provided by DOE-OBER.
grams in health measures and radiation biology conducted at the national laboratories. Subsequently, the Energy Reorganization Act of 1974 created ERDA, which assumed and expanded on AEC’s responsibilities. Three years later, the DOE was created. Within the DOE, the Office of Nuclear Energy (DOE-NE) provides radionuclides to the research community on a full-cost-recovery basis through its Isotope Program, while the DOE-OBER provides federal support for basic scientific studies in nuclear medicine through its Medical Applications and Measurement Sciences Program.
The mission of the program has been “to deliver relevant scientific knowledge that will lead to innovative diagnostic and treatment technologies for human health.” The specific objectives of the program are as follows (DOE 2006):
to utilize innovative radiochemistry to develop new radiotracers for medical research, clinical diagnosis, and treatment;
to develop the next generation of non-invasive nuclear medicine technologies;
to develop advanced imaging detection instrumentation capable of high resolution from the sub-cellular to the clinical level; and
to utilize the unique resources of the DOE in engineering, physics, chemistry, and computer sciences to develop the basic tools to be used in biology and medicine, particularly in imaging sciences, photo-optics and biosensors.
The program directly supported nuclear medicine research through radiopharmaceutical and instrument development and the development of